Considering that the PD-L1−PD-1 pathway may be associated with the pathophysiology of MM, anti-PD-1/PD-L1 antibody treatment could be clinically effective in MM patients by recovering T-cell cytotoxicity and inhibiting reverse signaling from PD-L1 on MM cells. The gene discussed is CD274; the disease is Miyoshi myopathy.